Aging Cell

Immunis Publishes Research Showing Secretomes Improve Metabolism and Muscle While Reducing Fat in Aged Models

Retrieved on: 
星期二, 三月 19, 2024
Men, Other Health, General Health, Pharmaceutical, Consumer, Infectious Diseases, Fitness & Nutrition, Biotechnology, Women, Alternative Medicine, Seniors, Vitamins, Supplements, Health, Metabolism, Adipose tissue, Obesity, Facial muscles, Connective tissue, Blood, Immunotherapy, Inc., Weight gain, Ageing, Fracture, Research, Mouse, DSM-IV codes, Aging Cell, University, Hope, Human, Muscle atrophy, Sarcopenic obesity, Therapy, Hospital, Dietary supplement

The study, published in Aging Cell, is entitled “ Stem cell secretome-treatment improves whole-body metabolism, reduces adiposity and promotes skeletal muscle function in aged mice .” The research examines the effects of Immunis’ investigational secretome on metabolism, fat and skeletal muscle in aged mouse models.

Key Points: 
  • The study, published in Aging Cell, is entitled “ Stem cell secretome-treatment improves whole-body metabolism, reduces adiposity and promotes skeletal muscle function in aged mice .” The research examines the effects of Immunis’ investigational secretome on metabolism, fat and skeletal muscle in aged mouse models.
  • As we age, our metabolic health declines and commonly manifests as obesity, muscle atrophy, and reduced physical function.
  • Dr. Drummond’s independent research in aged mouse models shows that Immunis’ immunotherapy, IMMUNA, increases whole-body lean mass and reduces fat mass, while increasing muscle fiber area.
  • Muscle quality improved such that there was an increase in muscle ‘stem’ cells, enhanced collagen turnover, more blood vessels and decreased muscle fat.

Immunis Chairman Dr. Hans Keirstead to Present Abundance360 Moonshot

Retrieved on: 
星期一, 三月 18, 2024
Surgery, Other Health, Other Science, Pharmaceutical, Oncology, Medical Devices, Infectious Diseases, Hospitals, Technology, Fitness & Nutrition, Clinical Trials, Stem Cells, Women, Science, Biotechnology, Practice Management, Seniors, Physical Therapy, Nanotechnology, Alternative Medicine, Managed Care, Medical Supplies, Men, FDA, Health, Diabetes, Consumer, Notifiable disease, Longevity, Facial muscles, Education, Patient, Ageing, Research, Sarcopenia, DSM-IV codes, Aging Cell, Quality of life, Human, Regenerative medicine, Safety, Fix, Muscle atrophy, Dietary supplement

Immunis, Inc., a private biotech company developing an innovative secretome for age-related diseases and immune dysfunction, announces that its Chairman, Dr. Hans Keirstead, will present at the annual Abundance360 in Los Angeles.

Key Points: 
  • Immunis, Inc., a private biotech company developing an innovative secretome for age-related diseases and immune dysfunction, announces that its Chairman, Dr. Hans Keirstead, will present at the annual Abundance360 in Los Angeles.
  • In fact, Abundance360 showcases “Moonshots,” or transformative ideas, from leaders who are making excellent strides to revolutionize human healthspan.
  • Dr. Keirstead’s Moonshot aims for the incredible goal of one day treating 500M individuals with Immunis’ investigational secretome (IMMUNA) to combat age-related immune dysfunction, targeting muscle atrophy and metabolic decline.
  • Dr. Keirstead’s Moonshot with IMMUNA aligns perfectly with his “Massive Transformative Purpose” to democratize regenerative medicine and enable everyone to live healthier lives.

HCW Biologics is Granted Third Fundamental Patent: U.S. Patent for Methods of Treating Age-Related Disorders

Retrieved on: 
星期三, 六月 14, 2023
Carcinoma, Tissue, Pancreatic cancer, Patent, 1836 U.S. Patent Office fire, Index, Masonic Cancer Center, University, University of Minnesota, Aging Cell, Hepatocellular carcinoma, Cancer, Ageing, Inflammation, SASP, Cellular senescence, Regeneration, Colorectal cancer, Melanoma, Immune system, Ovarian cancer, Notifiable disease, Stomach, Phenotype, Fish & Richardson, Safety, Breast cancer, Wound healing, Vaccine, Pharmaceutical industry

The patent also includes methods of use claims for killing or reducing the number of senescent cells by administering HCW9218 in subjects with cancer.

Key Points: 
  • The patent also includes methods of use claims for killing or reducing the number of senescent cells by administering HCW9218 in subjects with cancer.
  • Senescence is considered a physiologic process that is important in promoting wound healing, regeneration, and many other vital functions.
  • The U.S. Patent and Trademark Office recognized the methods of treating cancer using the novel immunotherapeutic, HCW9218.
  • This method of use patent will support a previously issued patent, U.S. Patent No.

HCW Biologics Reports First Quarter 2023 Financial Results And Recent Business Highlights

Retrieved on: 
星期二, 五月 9, 2023
Prejudice, Loss, Aging Cell, Bank statement, Clinical trial, Cancer, Lead, G&A, Research, Inflammation, Sale, Ageing, District court, Pitfalls, Investment, Publishing, Immune system, Court, R, Notifiable disease, Douglas v. U.S. District Court ex rel Talk America, Pharmaceutical industry, Cryptocurrency, Mouse

MIRAMAR, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its first quarter ended March 31, 2023.

Key Points: 
  • MIRAMAR, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its first quarter ended March 31, 2023.
  • Publishing ground-breaking scientific papers,” stated Dr. Hing C. Wong, Founder and CEO of HCW Biologics.
  • First Quarter 2023 Financial Results:
    Revenues: Revenues for the first quarter ended March 31, 2022 and 2023 were $3.1 million and $41,883, respectively.
  • Net loss: Net loss for the first quarter ended March 31, 2022 and 2023 was $2.1 million and $5.1 million, respectively.

A Novel Immunotherapeutic Approach to Treating Aging-Associated Diseases

Retrieved on: 
星期一, 四月 3, 2023
Tissue, Pancreatic cancer, Insulin resistance, DNA, Index, Masonic Cancer Center, University, Cellular senescence, Macular degeneration, Diabetes, University of Minnesota, Aging Cell, Osteoporosis, COVID-19, Cancer, Ageing, Lead, Kidney, Gene expression, Inflammation, Homeostasis, SASP, Sarcopenia, Fibrosis, Regeneration, Dementia, DNA repair, Metabolism, Patient, Apoptosis, Immune system, Mouse, Liver, Growth arrest lines, Longevity, Notifiable disease, Phenotype, Gene, HCW, Safety, Wound healing, Pharmaceutical industry, Vaccine

MIRAMAR, Fla., April 03, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, published a pivotal scientific paper in Aging Cell entitled, “Immunotherapeutic approach to reduce senescent cells and alleviate senescence-associated secretary phenotype in mice,” with Dr. Hing C. Wong, the Company’s Founder and CEO, as lead and corresponding author. The Company is currently evaluating one of its lead product candidates, HCW9218, a bifunctional immunotherapeutic compound, in patients with chemo-resistant/chemo-refractory advanced pancreatic cancer and solid tumors. In this publication, the Company demonstrates HCW9218 may have much broader therapeutic potential beyond cancer to other age-related diseases and conditions because of its ability to promote cell-mediated mechanisms to reduce senescent cells and alleviate the proinflammatory factors they secrete, known as senescence-associated secretory phenotype (“SASP”) factors, as shown in mice.

Key Points: 
  • This drives aging and age-related diseases, such as diabetes, osteoporosis, fibrotic diseases, cardiovascular diseases, dementia, renal failure, sarcopenia, macular degeneration, and neurodegenerative diseases, as well as other conditions such as long-haul COVID-19.
  • Dr. Wong founded HCW Biologics in 2018 with the vision of discovering novel immunotherapeutics to treat age-related diseases and improve healthspan.
  • Dr. Wong stated, “We believe that HCW9218 has the potential to redefine the approach for treating aging conditions and age-related diseases.
  • These data point toward the possibility that we have created a new class of immunotherapeutics for age-related diseases that will fundamentally change the way these diseases are treated.”

ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2022 Results

Retrieved on: 
星期三, 三月 8, 2023
Research, Seniors, Genetics, Biotechnology, Health, Consumer, Pharmaceutical, General Health, Science, Science Advances, Sinopharm (company), Security (finance), Coronavirus Scientific Advisory Board, Webcast, G&A, Aging Cell, Brain, Acquisition, Neurodegenerative disease, Biomarker, Growth, NHNE, Replay, NAD, Partnership, GAAP, Annual report, Regulation, EBITDA, Investment, Tru, ChromaDex, COVID-19, Conference, WalletHub, R, Trial of the century, NR, Marketing, Ageing, NRH, Cryptocurrency, Pharmaceutical industry, Reinsurance, Video game, Dietary supplement, Fine chemical, Bookkeeping

ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2022 financial results.

Key Points: 
  • ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2022 financial results.
  • ChromaDex also holds two patents covering crystal forms of important intermediates in the production of NR Chloride, one of which was granted in 2022.
  • “ChromaDex proudly reported its best quarter ever, achieving $21.0 million in revenue in the fourth quarter, up 18% year-over-year and 23% sequentially,” said Rob Fried, ChromaDex Chief Executive Officer.
  • A live webcast will be held Wednesday, March 8, 2023 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss ChromaDex’s fourth quarter and fiscal year 2022 financial results and provide a general business update.

ChromaDex Shares Promising Findings from Clinical Study Demonstrating Oral Supplementation with Nicotinamide Riboside (NR) Increased Nicotinamide Adenine Dinucleotide (NAD+) Levels in the Brain and Positively Impacted Neurodegenerative Biomarkers

Retrieved on: 
星期二, 十二月 27, 2022
Science, Seniors, Biotechnology, Research, Pharmaceutical, Health, Consumer, Clinical Trials, University of Delaware, Clinical trial, PD, Insulin resistance, Central nervous system, Timeline of Genesis patriarchs, Nature Communications, Protein, Phosphoprotein, Research, Neurodegeneration, National Institute on Aging, DNA, Brain, Biomarker, NIA, Inflammation, Trial of the century, Metabolism, Tissue, Patient, Plasma, Seminal vesicles, Pathology, Neuron, University, Kinesiology, Aging Cell, NEV, Ageing, Human, Paper, ChromaDex, AD, RNA, Cell, Pharmaceutical industry, Medical imaging, Medical device, NEVS

The study investigated whether NR would positively augment nicotinamide adenine dinucleotide (NAD+) levels and impact markers of neurodegenerative disease and insulin signaling in neuron-derived extracellular vesicles (NEVs) found in blood plasma.

Key Points: 
  • The study investigated whether NR would positively augment nicotinamide adenine dinucleotide (NAD+) levels and impact markers of neurodegenerative disease and insulin signaling in neuron-derived extracellular vesicles (NEVs) found in blood plasma.
  • NEVs are nano-sized particles that are released by neurons in the central nervous system, including the brain, and circulate in blood plasma.
  • The present study demonstrated that oral supplementation with NR significantly increased NAD+ levels in NEVs and attenuated neurodegenerative biomarkers including Aβ42, a biomarker for Alzheimer’s disease (AD).
  • Such results are promising and will set the foundation for further research evaluating NR supplementation in neurodegenerative disorders.

New Study shows Urolithin A (Mitopure®) Improves Mitochondrial Health, Reduces Joint Cartilage Damage and Alleviates Pain in Osteoarthritis

Retrieved on: 
星期四, 七月 7, 2022
Research, Fitness & Nutrition, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Cell, Recycling, FDA, Scripps Research, Ageing, Patient, Knee, CEO, Research, Tissue, OA, Molecular medicine, DOI, Nature Medicine, Pomegranate, Multimedia, Cartilage, Osteoarthritis, Swiss Federal Institute of Technology, Swiss Federal Institute of Aquatic Science and Technology, Food, Inflammation, EPFL, Regeneration, Mitophagy, Partnership, Mitochondrion, Organelle, D Grubu, UA, List of Nature Research journals, Quality of life, Paper, Invention, European Journal of Clinical Nutrition, Urolithin A, Solution, Human, GRAS, Aging Cell, Joint, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Eating, JAMA Network Open, European Journal, Dietary supplement, Pharmaceutical industry

This is the first time a compound has been shown to improve mitochondrial health in an experimental model of osteoarthritis (OA).

Key Points: 
  • This is the first time a compound has been shown to improve mitochondrial health in an experimental model of osteoarthritis (OA).
  • View the full release here: https://www.businesswire.com/news/home/20220707005266/en/
    This study showed that treatment with Amazentis proprietary Urolithin A, Mitopure, significantly improved mitochondrial health in human cartilage cells taken from both healthy and OA knee joints.
  • Previous research has shown Mitopure can improve mitochondrial health and muscle function in both older and middle-aged human populations.
  • Osteoarthritis is the most common age-related joint disorder, characterized by degradation of cartilage and other tissues, severe pain, and impaired mobility.